ABSTRACT
Introducción: El tratamiento antimicrobiano para los pacientes neutropénicos febriles (NF) se ha convertido en un desafío debido a la emergencia de microorganismos multirresistentes (MOR). El objetivo de este trabajo es analizar las características de estos pacientes y la incidencia de MOR. Materiales y métodos: Estudio retrospectivo, observacional y descriptivo desde junio de 2015 hasta agosto de 2017 en adultos neutropénicos febriles hospitalizados en un hospital público de la ciudad de Buenos Aires. Se analizaron características demográficas, clínicas y microbiológicas, incluyendo los siguientes MOR: enterobacterias productoras de carbapenemasas (EPC) y beta-lactamasas de espectro extendido (BLEE), Acinetobacter baumannii complex, Enterococcus vancomicina resistente (EVR) y Stenotrophomonas maltophilia. Resultados: Fueron incluidos 32 pacientes, 56% mujeres con 84% de neoplasias hematológicas. Hubo colonización por EPC o EVR en el 59% de los pacientes. Se registraron 148 episodios infecciosos con 41% de documentación microbiológica. Los MOR fueron responsables del 25% de los episodios, siendo los más frecuentes Klebsiella pneumoniae productora de carbapenemasa y BLEE; los focos más frecuentes fueron bacteriemias e infecciones urinarias. Los pacientes con leucemias agudas (67%) presentaron colonización por EPC o EVR en el 80%. El tratamiento fue inadecuado en el 63% de las infecciones RESUMENARTÍCULO ORIGINALpor MOR y en el 12% por microorganismos sensibles (MS) (p<0,01). La mortalidad global fue 53% con MOR y del 27% con MS (p=ns). Conclusión: las infecciones por MOR fueron frecuentes con predominio de bacteriemias, especialmente EPC y BLEE. Por ello los MOR deben ser tenidos en cuenta para el tratamiento empírico en pacientes neutropénicos febriles
Background: Antimicrobial treatment for febrile neutropenic (FN) patients has become a challenge due to the growing emergence of multidrug-resistant microorganisms (MDR-MO). The objective of this study was to analyze the characteristics of these population and the incidence of MDR-MO. Methods & Materials: Retrospective, observational and descriptive study from June 2015 to August 2017 in FN adults hospitalized at a public hospital in Buenos Aires city, Argentina. Demographic, clinical and microbiological characteristics were analyzed. We included the following MDR-MO: extended spectrum beta-lactamase (ESBL) and carbapenemase-producing Enterobacteriaceae (CPE), Acinetobacter baumannii complex, vancomycin resistant Enterococcus (VRE) and Stenotrophomonas maltophilia. Results: Thirty-two patients were included; 56% were women, with 84% haematological diseases. Colonization by CPE or VRE was observed in a 59% of the patients. There were 148 infectious episodes. Of them 41% had microbiological documentation. MDR-MO were responsible for 25% of the episodes and the most frequent were carbapenemase-producing Klebsiella pneumoniae and ESBL producing Enterobacteriaceae. MDR-MO were isolated mainly from bacteremia and urinary infections, patients had acute leukemia in a 67% and colonization CPKP or VRE in 80%. Inadequate treatment for MDR-MO was observed in 63% of the cases and 12% for susceptible microorganisms (p<0,01). The mortality was 53% for MDR-MO and 27% for susceptible microorganisms (p=ns). Conclusion: MDR-MO infections were frequent with predominance of bacteremia especially CPE and ESBL producing Enterobacteriaceae. According to these results MDR-MO should be taken into account for the empiric antimicrobial treatment in febrile neutropenic patients
Subject(s)
Humans , Adult , Middle Aged , Aged , Drug Resistance, Microbial , Epidemiology, Descriptive , Retrospective Studies , Enterobacteriaceae Infections/therapy , Febrile Neutropenia/therapy , Carbapenem-Resistant Enterobacteriaceae , Hospitalization , NeoplasmsABSTRACT
La leucemia aguda ha sido reconocida como una enfermedad compleja y rápidamente fatal desde su primera descripción hace 150 años. Librada a su historia natural, la leucemia mieloide aguda lleva a la muerte en pocos meses. Las infecciones son la principal causa de muerte, siendo la bacteriemia y la neumonía las más frecuentes.Los avances ocurridos en los últimos 50 años, como el advenimiento de quimioterapias efectivas, la mejor comprensión de la patogénesis de las complicaciones infecciosas en el paciente neutropénico, la disponibilidad de agentes anti infecciosos de amplio espectro y la mejoría en los cuidados de soporte contribuyeron a mejorar esta situación. En relación a otras enfermedades oncohematológicas, la leucemia mieloide aguda registra la mayor incidencia de eventos febriles, siendo el período de mayor riesgo el de la inducción a la remisión.La fiebre de origen desconocido, la multirresistencia bacteriana y las infecciones fúngicas invasivas constituyen un desafío para el equipo de trabajo.El uso de profilaxis antibacteriana y antifúngica no reemplaza a las medidas de prevención de carácter institucional
Acute leukemias have been recognized as complex and radiply fatal diseases since its first description 150 years ago. Delivered to its natural history, acute myeloid leukemia leads to death in a few months. Infections are the main cause of death, being bacteremia and pneumonia the most frequent. Advances in the last 50 years, such as the advent of effective chemotherapy, a best understanding of the pathogenesis of infectious complications in the neutropenic patient, the availability of broad-spectrum anti-infective agents and better supportive care helped improve this situation. Among other oncological diseases, acute myeloid leukemia has the highest incidence of febrile events, being induction to remission the period of greatest risk. Fever of unknown origin, bacterial multidrug resistance and invasive fungal infections are a challenge for the medical team. The use of antibacterial and antifungal prophylaxis does not replace institutional preventive measures
Subject(s)
Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/therapy , Antibiotic Prophylaxis , Drug Therapy , Febrile Neutropenia/therapyABSTRACT
Introdução: A neutropenia febril (NF) é uma das mais graves complicações em pacientes com câncer submetidos a quimioterapia. Estes casos exigem pronta avaliação diagnóstica e instituição de terapêutica adequada. A conduta frente a tal emergência ainda é muito discutida apesar dos avanços no tratamento. O objetivo do estudo foi revisar na literatura as medidas mais eficazes de manejo sindrômico da NF. Métodos: Este artigo é uma revisão bibliográfica realizada entre abril e maio de 2018 sobre neutropenia febril. Foi realizada pesquisa de artigos científicos de revisão, guidelines e artigos originais, dos últimos 15 anos. Resultados: O reconhecimento imediato do paciente com NF e seu adequado tratamento com início imediato de terapia empírica, conforme o risco do paciente, são definidores de qualidade do manejo desta síndrome. Conclusão: A avaliação inicial de todos os pacientes com NF deve ser ágil para que terapia empírica seja imediatamente iniciada.
Introduction: Febrile neutropenia (NF) is one of the most serious complications in cancer patients undergoing chemotherapy. These cases require prompt diagnostic evaluation and management. The objective of the study was to review the most effective aspects of NF syndromic management in the literature. Methods: This article is a bibliographical review performed between April and May of 2018 on febrile neutropenia. Research was done on review articles, seminars and original articles of the last 15 years. Results: The immediate recognition of the patient with NF and its appropriate treatment with immediate onset of empirical therapy, according to the risk of the patient, are critical and impact clinical outcomes. Conclusion: The initial assessment of all NF patients should be agile for empirical therapy to be initiated immediately.
Subject(s)
Febrile Neutropenia , Febrile Neutropenia/diagnosis , Febrile Neutropenia/therapy , NeoplasmsABSTRACT
As infecções constituem uma causa comum e agravante de morbi-mortalidade em pacientes que apresentam uma ampla variedade de neoplasias malignas. Isto ocorre devido à imunodeficiência gerada tanto por aspectos intrínsecos ao crescimento tumoral como pelo tratamento quimioterápico, que facilita assim a ocorrência de quadros infecciosos graves e muitas vezes de difícil manejo. Orientar a suspeita diagnóstica e o manejo inicial do paciente neutropênico febril são os objetivos desse artigo de revisão.
Infections are a common cause and aggravating factor of morbidity and mortality in patients with a wide variety of malignancies. This occurs because of the immunodeficiency generated either by intrinsic tumor growth by as chemotherapy aspects, so facilitates the occurrence of serious infectious conditions and often difficult to manage. Guide the suspected diagnosis and initial management of febrile neutropenic patients are the aims of this review article.